ImmunoGen, Inc. (NASDAQ:IMGN) CFO David Brannon Johnston sold 10,000 shares of the stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $11.53, for a total value of $115,300.00. Following the completion of the transaction, the chief financial officer now owns 190,690 shares of the company’s stock, valued at approximately $2,198,655.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
David Brannon Johnston also recently made the following trade(s):
- On Wednesday, February 21st, David Brannon Johnston sold 21,060 shares of ImmunoGen stock. The stock was sold at an average price of $10.87, for a total value of $228,922.20.
ImmunoGen, Inc. (IMGN) traded up $0.39 during midday trading on Friday, hitting $12.22. The stock had a trading volume of 7,202,404 shares, compared to its average volume of 2,822,789. ImmunoGen, Inc. has a 52-week low of $2.84 and a 52-week high of $12.38. The stock has a market capitalization of $1,571.57, a PE ratio of -11.98 and a beta of 2.17. The company has a debt-to-equity ratio of -0.11, a quick ratio of 4.94 and a current ratio of 4.95.
ImmunoGen (NASDAQ:IMGN) last released its earnings results on Friday, February 9th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The firm had revenue of $39.40 million during the quarter, compared to analysts’ expectations of $39.62 million. During the same quarter in the prior year, the company posted ($0.39) earnings per share. The company’s revenue was up 185.5% on a year-over-year basis. equities research analysts expect that ImmunoGen, Inc. will post -1.09 earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its stake in shares of ImmunoGen by 75.7% in the fourth quarter. SG Americas Securities LLC now owns 18,416 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 7,937 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of ImmunoGen in the second quarter worth $126,000. Virginia Retirement Systems ET AL purchased a new stake in shares of ImmunoGen in the third quarter worth $136,000. Cubist Systematic Strategies LLC purchased a new stake in shares of ImmunoGen in the third quarter worth $143,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of ImmunoGen in the fourth quarter worth $149,000. 78.60% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have issued reports on the company. HC Wainwright set a $18.00 price objective on ImmunoGen and gave the stock a “buy” rating in a report on Monday, March 12th. ValuEngine upgraded ImmunoGen from a “sell” rating to a “hold” rating in a report on Wednesday, March 7th. Zacks Investment Research downgraded ImmunoGen from a “hold” rating to a “sell” rating in a report on Friday, February 23rd. BidaskClub upgraded ImmunoGen from a “buy” rating to a “strong-buy” rating in a report on Friday, February 9th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $12.00 price objective on shares of ImmunoGen in a report on Thursday, February 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. ImmunoGen has an average rating of “Buy” and a consensus price target of $10.21.
COPYRIGHT VIOLATION WARNING: “ImmunoGen, Inc. (IMGN) CFO David Brannon Johnston Sells 10,000 Shares” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://ledgergazette.com/2018/03/17/immunogen-inc-imgn-cfo-david-brannon-johnston-sells-10000-shares.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.